EvuShield demanded for prophylaxis by immunocompromised people in the UK – who remain under virtual house arrest
From here:
Meet the 'abandoned' Covid victims still in lockdown with vaccines having no effect (msn.com)
“Speaking to Express.co.uk, campaign group Evusheld for the UK said: "For this group of patients the pandemic is not over, they still continue to live through the nightmare which impacts their families, finances and mental health, too many lives have also been lost.”
“Jane, like many patients, is annoyed by the decision of the government not to roll out Evusheld, adding that she feels the immunosuppressed have been "abandoned".
She said: "If the UK had given us Evusheld when MRHA approved it in March 2022 our lives would have been transformed. Instead, it got referred to NICE who took many months to evaluate it and finally decided not to roll it out."
No doubt there are all sorts of hoops to go through to get a patient preferred treatment.
From here:
Evusheld approved to prevent COVID-19 in people whose immune response is poor - GOV.UK (www.gov.uk)
Published 17 March 2022 “A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting the UK regulatory standards of safety, quality and effectiveness.”
Not sure how to square that circle, no doubt the devil is in the detail.
How much does it cost?
Evusheld available in the UK to buy privately | Blood Cancer UK
“Evusheld (tixagevimab/cilgavimab) will cost a private healthcare provider £1,000 per dose (£1,200 including VAT). Each dose is 600mg (containing 300mg of tixagevimab and 300mg of cilgavimab). This is the recommended dose for an individual person.
While the private provider will pay £1,200 per dose, they will need to charge their patients more than this. There might be a charge for the consultation, plus the charge for the actual treatment. This means the cost to patients will be over £1,200. It's not possible to say exactly how much, as it will depend on how much the provider decides to charge.”
Package leaflet details here:
Patient Information Leaflet for Evusheld - GOV.UK (www.gov.uk)
How “safe and effective”?
Evusheld | European Medicines Agency (europa.eu)
“One main study involving over 5,000 people showed that Evusheld reduced the risk of COVID-19 infection by 77%, with duration of protection from the virus estimated to be at least six months.”
“Of the people given Evusheld, 0.2% (8 out of 3,441) had lab-confirmed breakthrough COVID-19, compared with 1% (17 out of 1,731) of the people who received placebo.”
Okay, so 0.8% absolute reduction in cases, but “The study data were collected before the emergence of the Omicron variant.”
Let’s see what the C19 treatment database has to show:
Tixagevimab/cilgavimab for COVID-19: real-time analysis of all 11 studies (c19early.org)
Looks good on the face of it, but
“Tixagevimab/cilgavimab COVID-19 studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, and BQ.1.1 [Planas]. US EUA has been revoked. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary].”
US EUA has been revoked. Of course, that could mean it works well, given the track record of the FDA/CDC.
Here’s chart of different studies for EvuShield and Ivermectin for prophylaxis:
For Ivermectin:
Closer “apples with apples” needed for prophylaxis comparisons.
COVID-19 early treatment: real-time analysis of 2,623 studies (c19early.org)
Maybe Ivermectin is contra-indicated for immunocompromised people. Maybe Astra Zeneca does a better job at binding to the spike protein in the outside of the virus.
One thing is for sure, the UK government/Oxford University continues to slow roll the results of a study on Ivermectin that has now run for almost two years.
Remember this from June 2021?
Commentary on its withdrawal here:
And then this resurrection from May 2022?
“The PRINCIPLE Trial has led the way in evaluating treatments for COVID-19 in the community over the past two years. It has tested five potential treatments so far, with a further two, favipiravir and ivermectin, still being studied in the trial.”
Maybe it will be released next week. (/s).
Onwards!
Please subscribe, or donate a coffee (I drink a lot of coffee) - “God Bless You!” if you can’t or don’t want to contribute. Coffee donations here: https://ko-fi.com/peterhalligan
Covid 19 a failed experiment
Faculty of medicine need a kick in the nuts
Not that the department of virology ever neared a moon shot. Clearly they missed more often than not.
Soft science should ask for help, god mows the need it.
Thanks PH. Evil just pure evil by fcUKdup govtards & every single one of their initialed bs government agencies.